United Health Products (UEEC) Q3 2025 earnings summary

Executive summary

• Focused on obtaining FDA Class III PMA for CelluSTAT hemostatic gauze, pausing commercial activities to prioritize regulatory approval.

• Submitted PMA application in March 2024; FDA requested additional data and issued a Warning Letter regarding clinical procedures.

• IDE application for a supplemental clinical trial was disapproved in April 2025 due to unresolved FDA Warning Letter; company is engaging with FDA to resolve issues.

• Considering strategic alternatives, including sale, merger, or commercial partnerships, pending regulatory outcome.

Financial highlights

• No revenue generated for the three and nine months ended September 30, 2025, as resources were focused on regulatory efforts.

• Net loss for Q3 2025 was $285,594, a slight improvement from $303,662 in Q3 2024, due to lower operating expenses.

• Net loss for the nine months ended September 30, 2025 was $2,132,440, up from $1,187,621 in the prior year period, driven by increased stock-based compensation.

• Operating expenses for the nine months rose to $1,990,751 from $1,222,174 year-over-year, mainly due to RSU vesting.

Outlook and guidance

• Uncertainty remains regarding the timing and outcome of FDA approval for CelluSTAT.

• Company evaluating capital raising alternatives after expiration of its equity purchase agreement with White Lion.

• No assurance of continued financing or regulatory approval; strategic options under review.